The Lancet Neurology
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
By Giuseppe Plazzi, Ronald R. Grunstein, Emmanuel Jean-Marie Mignot, Show 10 more authorsYves A Dauvilliers
Trial in peopleInterventions
The paper
University of Modena and Reggio Emilia; Inserm
The Lancet Neurology, 24 Aug 2026
